Eli Lilly, Novo Nordisk Shares Dip as Pfizer Ramps Up Diabetes Drug Competition

Shares of $Eli Lilly and Co(LLY.US)$ and $Novo-Nordisk A/S(NVO.US)$ finished lower on Thursday, perhaps influenced by competitive developments and regulatory updates in the pharmaceutical sector.

Benzinga16:12 ET

Gilead Sciences's Options Frenzy: What You Need to Know

Deep-pocketed investors have adopted a bearish approach towards Gilead Sciences (NASDAQ:GILD), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga

Benzinga15:48 ET

The weight-loss drug market is too lucrative to be abandoned! After being hit, Pfizer has restarted.

Pfizer, a world-renowned pharmaceutical company, has decided to enter the lucrative weight loss drug market to improve its performance, which has been affected by the post-pandemic slump. Pfizer first evaluated the prospects of the weight loss drug market and estimated that the market will grow to around USD 130 billion in the next ten years, with oral tablets expected to account for about one-third of the market. As a result, Pfizer hopes to compete with Novo Nordisk and Eli Lilly and Co.'s popular injectable weight loss drugs by developing an oral weight loss drug called danuglipron. This oral weight loss drug does not require injections and is expected to rival traditional injectable drugs. However, Pfizer has been struggling to make progress in treating obesity.

wallstreetcn13:56 ET

Why Pfizer Stock Is Moving Higher on Thursday

Pfizer (NYSE:PFE) stock gained on Thursday after the company announced it will advance development of its once-daily Danuglipron.

Benzinga13:34 ET

Check Out What Whales Are Doing With AMGN

Investors with a lot of money to spend have taken a bullish stance on Amgen (NASDAQ:AMGN).And retail traders should know.We noticed this today when the trades showed up on publicly available options

Benzinga13:32 ET

Amgen Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 -5.77% Morgan Stanley $310 → $303 Maintains Equal-Weight 06/27/2024 5.73% Argus Research $300 →

Benzinga13:05 ET